Late metachronous cerebral metastasis of pancreatic adenocarcinoma of the tail of the pancreas: a case report

Papadimitriou, Kyriakos; Kiss-Bodolay, Daniel; Hedjoudje, Abderrahmane; Millán, Diego San; Simonin, Alexandre; Fournier, Jean–Yves; Huscher, Karen

doi:10.1186/s13256-022-03314-w

Cited by 3 publications

(1 citation statement)

References 25 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18F-fluorodeoxyglucose uptake in pancreatic lesions was confirmed in patients who could perform FDG-PET. Then, based on images of pathologically-confirmed pancreatic metastasis from lung cancer [16][17][18][19][20][21][22][23][24][25][26], a diagnosis was made in the following conditions:…”

Section: • Confirmation Of Sclcmentioning

confidence: 99%

Distant organ metastasis patterns in lung cancer patients with pancreatic metastasis – a cluster analysis

Okauchi¹,

Miyazaki²,

Shiozawa³

et al. 2022

View full text Add to dashboard Cite

Introduction: Pancreatic metastasis of lung cancer is rare, but the narrowing or obstruction of the biliary tract from pancreatic metastases limits the choice of antitumour agents. Lung cancer patients with pancreatic metastasis often have metastasis of other organs. For these patients, however, no studies have been conducted to evaluate distant metastasis sites as metastasis patterns. This study aims to assess whether these patients have specific metastasis patterns at the time of diagnosis of lung cancer. Material and methods: Data were collected from consecutive lung cancer patients with pancreatic metastasis between April 2012 and March 2022. Metastatic patterns were analysed using cluster analysis in patients with lung cancer. Results: During the study period, 33 (2.0%) of 1659 patients were diagnosed as having pancreatic metastasis. Of the 33 patients, 28 (84.8%) were male. Eighteen, 14, and one patient had small cell lung cancer (SCLC), lung adenocarcinoma, and large cell neuroendocrine carcinoma, respectively. They were divided into 3 groups by cluster analysis. A statistically significant difference in metastasis frequency was confirmed among these 3 groups (χ 2 test, p = 0.001). Conclusions: In lung cancer patients with pancreatic metastasis, knowledge of the metastatic patterns might be useful for clinical practice in the foreseeable future because it enables more efficient detection of metastatic disease through imaging, and more effective treatment at predicted metastatic sites.

show abstract

Section: • Confirmation Of Sclcmentioning

confidence: 99%

Distant organ metastasis patterns in lung cancer patients with pancreatic metastasis – a cluster analysis

Okauchi¹,

Miyazaki²,

Shiozawa³

et al. 2022

View full text Add to dashboard Cite

show abstract

Metástasis cerebral múltiple de adenocarcinoma pancreático. Reporte de caso

Alonso Bracho,

Arroyo Zavala,

Laredo Gómez

et al. 2024

Rev Fac Med

View full text Add to dashboard Cite

Introduction: Brain metastases are the most common malignant lesions in the central nervous system. Brain metastases from pancreatic cancer are very rare, with poor prognosis. The present paper aims to describe a rare pathology and the work carried out for the patient's care. Case report: 49-year-old man with personality changes, depression, and apathy. Five days before admission, he presented dysarthria, added left hemiparesis, and disorientation that progressed to sudden neurological deterioration that required advanced airway management. A computed tomography study was seen with cerebral cystic lesions. A decompressive craniectomy and drainage of the larger lesión was performed, with subsequent resection. The study protocol with immunohistochemistry reports CK 19, compatible with pancreatic adenocarcinoma. Conclusions: A rare case of multiple brain metastases and suspected lung metastasis, both secondary to primary pancreatic adenocarcinoma was presented. The patient began with symptoms associated with brain lesions. The incidence of brain metastases with a primary pancreatic tumor is very low, and this is an exceptional case when presenting with neurological symptoms. Surgical resection of the brain lesion had a limited role in the clinical improvement of the patient since the progression of the disease was rapid. Still, it was useful to establish a diagnosis by immunohistochemistry. Since there are no screening tests for pancreatic tumors, it is difficult to identify them in early stages and without gastrointestinal symptoms. Keywords: Pancreatic adenocarcinoma; brain tumors; brain metastases; cytokeratin 19; immunohistochemistry.

show abstract

Management and outcomes of brain metastases from pancreatic adenocarcinoma: a pooled analysis and literature review

Gouton,

Gilabert,

Launay

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundBrain metastases (BM) are rare in pancreatic ductal adenocarcinoma (PDAC) and little data exists concerning these patients and their outcomes.AimWe aimed to analyze the management, practices, and outcomes of patients presenting BM from PDAC both in our institution and in all cases reported in the literature.MethodsWe conducted a retrospective, monocentric analysis using a data mining tool (ConSoRe) to identify all patients diagnosed with PDAC and BM in our comprehensive cancer center (Paoli-Calmettes Institute), from July 1997 to June 2022 (cohort 1). Simultaneously, we reviewed and pooled the case reports and case series of patients with PDAC and BM in the literature (cohort 2). The clinical characteristics of patients in each cohort were described and survival analyses were performed using the Kaplan-Meier method.ResultsIn cohort 1, 19 patients (0.3%) with PDAC and BM were identified with a median age of 69 years (range: 39-81). Most patients had metastatic disease (74%), including 21% with BM, at diagnosis. Lung metastases were present in 58% of patients. 68% of patients had neurological symptoms and 68% were treated by focal treatment (surgery: 21%, radiotherapy: 42%, Gamma Knife radiosurgery: 5%). In cohort 2, among the 61 PDAC patients with BM described in the literature, 59% had metastatic disease, including 13% with BM at diagnosis. Lung metastases were present in 36% of patient and BM treatments included: surgery (36%), radiotherapy (36%), radiosurgery (3%), or no local treatment (25%). After the pancreatic cancer diagnosis, the median time to develop BM was 7.8 months (range: 0.0-73.9) in cohort 1 and 17.0 months (range: 0.0-64.0) in cohort 2. Median overall survival (OS) in patients of cohort 1 and cohort 2 was 2.9 months (95% CI [1.7,4.0]) and 12.5 months (95% CI [7.5,17.5]), respectively.ConclusionBM are very uncommon in PDAC and seem to occur more often in younger patients with lung metastases and more indolent disease. BM are associated with poor prognosis and neurosurgery offers the best outcomes and should be considered when feasible.

show abstract

Late metachronous cerebral metastasis of pancreatic adenocarcinoma of the tail of the pancreas: a case report

Cited by 3 publications

References 25 publications

Distant organ metastasis patterns in lung cancer patients with pancreatic metastasis – a cluster analysis

Distant organ metastasis patterns in lung cancer patients with pancreatic metastasis – a cluster analysis

Metástasis cerebral múltiple de adenocarcinoma pancreático. Reporte de caso

Management and outcomes of brain metastases from pancreatic adenocarcinoma: a pooled analysis and literature review

Contact Info

Product

Resources

About